A detailed history of Cutler Group LP transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Cutler Group LP holds 400 shares of KRYS stock, worth $76,160. This represents 0.0% of its overall portfolio holdings.

Number of Shares
400
Previous 200 100.0%
Holding current value
$76,160
Previous $24,000 75.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 18, 2024

BUY
$96.0 - $128.29 $9,600 - $12,829
100 Added 100.0%
200 $24,000
Q2 2023

Jul 18, 2023

SELL
$78.48 - $130.32 $9,810 - $16,290
-125 Reduced 55.56%
100 $11,000
Q2 2022

Aug 04, 2022

SELL
$48.93 - $73.47 $3,669 - $5,510
-75 Reduced 25.0%
225 $14,000
Q1 2022

Apr 14, 2022

SELL
$51.99 - $72.11 $435,208 - $603,632
-8,371 Reduced 96.54%
300 $19,000
Q4 2021

Jan 18, 2022

BUY
$39.81 - $88.24 $345,192 - $765,129
8,671 New
8,671 $606,000

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.89B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.